Gene · 1241
LTB4R: leukotriene B4 receptor
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. LTB4R: leukotriene B4 receptor. Genes, record 1241. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/1241
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| Q15722 | Leukotriene B4 receptor 1 | 352 | 2 | Ensembl, GeneID, HGNC |
Source UniProt
Patents52
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| JP 2026004568 A | 2026-01-14 | 51643 | Q15722 | Espacenet |
| JP 2026004568 A | 2026-01-14 | 51644 | Q15722 | Espacenet |
| JP 2026004568 A | 2026-01-14 | 51645 | Q15722 | Espacenet |
| JP 2025529142 A | 2025-09-04 | 2487 | Q15722 | Espacenet |
| US 12371689 B2 | 2025-07-29 | 2487 | Q15722 | Espacenet |
| US 11446398 B2 | 2022-09-20 | 46551 | Q15722 | Espacenet |
| US 11446398 B2 | 2022-09-20 | 46552 | Q15722 | Espacenet |
| US 11446398 B2 | 2022-09-20 | 46553 | Q15722 | Espacenet |
| US 11400116 B2 | 2022-08-02 | 1736 | Q15722 | Espacenet |
| US 11400116 B2 | 2022-08-02 | 6619 | Q15722 | Espacenet |
1 to 10 of 52
See all 52 patentsDrugs4
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
| Drug | ChEMBL ID | Mechanism | Action | Source |
|---|---|---|---|---|
| AMELUBANT | CHEMBL1742420 | Leukotriene B4 receptor 1 antagonist | ANTAGONIST | ChEMBL |
| CP-195543 | CHEMBL301829 | Leukotriene B4 receptor antagonist | ANTAGONIST | ChEMBL |
| ETALOCIB | CHEMBL329123 | Leukotriene B4 receptor 1 antagonist | ANTAGONIST | ChEMBL |
| NOMACOPAN | CHEMBL4297928 | Leukotriene B4 receptor inhibitor | INHIBITOR | ChEMBL |
Trials16
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
| Trial | Drug | Phase | Results first posted | Source |
|---|---|---|---|---|
| NCT05061771 | NOMACOPAN | PHASE3 | ClinicalTrials.gov | |
| NCT04784455 | NOMACOPAN | PHASE3 | 2025-05-15 | ClinicalTrials.gov |
| NCT04037891 | NOMACOPAN | PHASE1/PHASE2 | 2025-02-27 | ClinicalTrials.gov |
| NCT04035733 | NOMACOPAN | PHASE2 | ClinicalTrials.gov | |
| NCT03829449 | NOMACOPAN | PHASE3 | 2025-03-12 | ClinicalTrials.gov |
| NCT03588026 | NOMACOPAN | PHASE3 | ClinicalTrials.gov | |
| NCT03427060 | NOMACOPAN | PHASE2 | 2025-05-04 | ClinicalTrials.gov |
| NCT02591862 | NOMACOPAN | PHASE2 | 2023-07-12 | ClinicalTrials.gov |
| NCT02251210 | AMELUBANT | PHASE2 | ClinicalTrials.gov | |
| NCT02249338 | AMELUBANT | PHASE2 | ClinicalTrials.gov |
1 to 10 of 16
See all 16 trialsNIH grants1,080
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | LTB4R papers | Newest fiscal year |
|---|---|---|---|
| R35GM128641 | Structure, pharmacology and signaling of G protein-coupled receptors (GPCRs) in inflammation | 4 | 2025 |
| T32AI060519 | Immunology and Infectious Diseases Training Program | 4 | 2025 |
| P01HL116263 | HDL Function in Human Disease | 3 | 2025 |
| P30CA008748 | Cancer Center Support Grant | 3 | 2025 |
| P30ES010126 | UNC Center for Environmental Health and Susceptibility | 3 | 2025 |
| R01AR062173 | The IL-23/IL-17 Axis in Inflammatory Arthritis | 3 | 2025 |
| R35GM139430 | Evaluating Resolution Mechanisms for Infectious Inflammation | 3 | 2025 |
| ZIABC011763 | Regulation of epithelial cell fate decisions in tissue homeostasis and cancer | 3 | 2025 |
| P30CA010815 | Consolidated Basic Cancer Research Program | 2 | 2025 |
| P30CA014599 | Cancer Center Support Grant | 2 | 2025 |
1 to 10 of 1,080Source NIH's project files
See all 1,080 nih grantsPapers1,557
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Single-Cell RNA Sequencing Combined with MEBOCOST Reveals Alveolar Macrophage-Mediated Immunometabolic Communication Mechanisms in Sepsis-Induced Acute Lung Injury. | Genes (Basel) | 2026 | 42792913 | PubTator, text mining | PubMed |
| The 5-Lipoxygenase Pathway in Ovarian Cancer: Mechanisms of Metastasis, Chemoresistance, and Translational Targeting. | Int J Womens Health | 2026 | 42763661 | PubTator, text mining | PubMed |
| Benzo[a]pyrene-induced METTL3 overexpression accelerates renal cell carcinoma progression via m6A modification of LTB4R mRNA and enhanced Treg infiltration. | Ecotoxicol Environ Saf | 2026 | 42628180 | PubTator, text mining | PubMed |
| In vivo CRISPR screening identifies LTA4H as a target for potentiating immunotherapy efficacy via the LTB4-neutrophil axis. | Int Immunopharmacol | 2026 | 42537346 | PubTator, text mining | PubMed |
| Identification of immune-related prognostic genes and construction of a risk model for Wilms tumor: A retrospective bioinformatics study. | Medicine (Baltimore) | 2026 | 42499033 | PubTator, text mining | PubMed |
| Mechanisms by which macrophage Ltb4r1 mediates tubular epithelial cell injury to facilitate the advancement of diabetic kidney disease. | BMC Nephrol | 2026 | 42420893 | PubTator, text mining | PubMed |
| Redox-sensitive GPCR signaling drives Gq-dependent Ca2+ mobilization and cytokine production in human bronchial epithelial cells. | Am J Physiol Cell Physiol | 2026 | 42314770 | PubTator, text mining | PubMed |
| Crosstalk between immune and programmed cell death and their application in colorectal cancer risk stratification. | Mol Clin Oncol | 2026 | 42124937 | PubTator, text mining | PubMed |
| Ochratoxin A and Clear Cell Renal Cell Carcinoma: Exploring Potential Molecular Links Through Network Toxicology and Machine Learning. | Int J Mol Sci | 2026 | 41977161 | PubTator, text mining | PubMed |
| Bach2 antagonizes leukotriene B4-Ltb4r1-JunB signaling to constrain Tfh13 cell differentiation. | Cell Rep | 2026 | 41950005 | PubTator, text mining | PubMed |
1 to 10 of 1,557
See all 1,557 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/1241
GET https://conductscience.org/api/genes/v1/1241/patents?page=2